Advice
following a full submission:
sofosbuvir-velpatasvir (Epclusa®) is accepted for restricted use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults.
SMC restriction: in patients with genotype 3 (GT3) chronic HCV infection.
Sofosbuvir-velpatasvir for 12 weeks, compared with sofosbuvir plus ribavirin for 24 weeks, significantly improved sustained virologic suppression in adults with genotype 3 chronic HCV infection.
Download detailed advice206KB (PDF)
Medicine details
- Medicine name:
- sofosbuvir/velpatasvir (Epclusa)
- SMC ID:
- 1195/16
- Indication:
- Treatment of chronic hepatitis C virus (HCV) infection in adults.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 November 2016